Biotech Showcase 2019 Investment Trends Survey

Size: px
Start display at page:

Download "Biotech Showcase 2019 Investment Trends Survey"

Transcription

1 Demy-Colton and EBD Group Biotech Showcase 2019 Investment Trends Survey December 7, 2018

2 Survey Overview Survey included 10 questions on biotech industry investment trends for 2019 Survey was sent to the 2018 list of registered Biotech Showcase attendees 80 people provided responses

3 QuesBon 1: Which of the following best describes your professional role? Venture capitalist Corporate investor Investment banker/banker Private investor Buy side/sell side research analyst Executive or upper management of biotech or pharma company Research and development executive Government official Professional service provider Press and media

4 Survey Responder Demographics - Chart Professional Press and media, 3.75% service provider, 1 Buy side/sell side research analyst Corporate Investor Government official, Investors, 33.75% 5.00% 7.50% 16.25% Investment Banker Private Investor Venture Capitalist Executives and Upper Management, 48.75% Based on 80 responses to survey

5 Survey Responder Demographics - Table RESPONDER OCCUPATION # OF RESPONDERS PERCENT OF TOTAL INVESTOR (Total of subcategories below) % Venture capitalist % Corporate investor 2 Investment banker/banker % Private investor % Buy side/sell side research analyst 2 EXECUTIVE/UPPER MANAGEMENT (Total of subcategories below) % Executive or upper management of biotech or pharma company % Research and development executive % Government official 2 Professional service provider 9 1 Press and media % Total Responders 80

6 Question 2: Overall, you expect to see in life science investments in 2019 compared to Increase Decrease No change

7 The majority of life science investors and executives expect to see an increase in investment during % 60% 50% 7.50% Investors Executives Media, Services, Gov 40% 37.50% 30% 20% 6.25% 10% 0% 20.00% 3.75% 8.75% 6.25% 7.50% Increase Decrease No Change

8 Sixty percent of life science investors expect to see an increase in investment in % 60% 50% 40% 30% 20% 10% 0% Increase Decrease No Change

9 Question 3: Of the following areas, which do you think is poised to have the biggest nearterm breakthrough? Alzheimer s and CNS diseases Cell and gene therapy Immuno-oncology NASH RNA therapeutics Rare and orphan disease Digital medicine Other (please specify)

10 Of the major therapeutic areas, biotech leaders think cell and gene therapy is poised to have biggest breakthrough in % 30% 3.75% 25% 20% % 15% 10% 5% 0% Cell and gene therapy % 7.50% 5.00% 6.25% 3.75% Immuno-oncology Rare and orphan disease Digital medicine Alzheimer s and CNS 5.00% NASH RNA therapeutics 3.75% Other

11 Question 4: Of the factors listed below, what is the biggest challenge biotech companies face in securing funds in the coming year? Crowded market or sector Economic volatility Inexperienced management team Lack of achieved milestones Inability to manage pipeline progression or clinical trials Other (please specify)

12 Biggest challenges for securing funds in the coming year are crowded markets, economic volatility, and inexperienced management 25% 20% 15% 10% 5% 0% Crowded market or sector Economic volatility Inexperienced management team Lack of achieved milestones Inability to manage pipeline progression or clinical trials Other

13 US Outlook

14 Question 5: Do you expect the recent stock market volatility to affect overall biotech investment in 2019? Yes No Unsure

15 Most biotech leaders expect the stock market volatility to have an overall effect on 2019 investments 70% 60% 50% 1 40% 27.50% 30% 20% 3.75% 10% 20.00% % 0% 7.50% 6.25% Yes No Unsure

16 Question 6: What US city/region will see the biggest percent increase in investment dollars in the biotechnology industry in 2019? Boston Los Angeles New York Philadelphia Raleigh-Durham San Diego San Francisco Seattle Other (please specify)

17 Boston holds #1 seat for predicted influx of investment dollars among the major U.S. cities 35% 30% 25% 10.00% 20% 15% 1 10% 5% 0% 8.75% 3.75% % 5.00% 8.75% 7.50% 5.00% 3.75% 3.75% 3.75% Boston San Diego San Francisco New York Other* Los Angeles Philadelphia Raleigh-Durham Seattle *Texas (3), New Jersey, Maryland

18 Investors think New York is the next city, after Boston and San Francisco, to see an influx of investment dollars in % 9% 8% 7% 6% 5% 4% 8.75% 7.50% 3% 2% 1% 0% Boston San Francisco 5.00% New York 3.75% 3.75% Other* Philadelphia San Diego Los Angeles Raleigh-Durham Seattle *Texas (3), New Jersey, Maryland

19 Global Outlook

20 Ques%on 7: Which region outside the United States will see the biggest percent increase in investment dollars in the biotechnology industry in 2019? China UK Germany Benelux Japan France Spain Scandinavia South Korea Other*

21 China predicted to see the biggest percent increase in 2019 biotech investment dollars when compared to other global biotech hot spots 50% 45% 40% 7.50% 35% 30% 25% 25.00% 20% 15% 10% 5% 0% 5.00% % 5.00% 5.00% 6.25% 3.75% China UK Germany Benelux Japan France Spain Scandinavia S. Korea Other* *Israel (3), Singapore, Unspecified

22 Question 8 & 9: What impact will US/China trade war have on strategy for investment, partnerships, or expansion in China? Negative Impact No Impact Will this trade war have a long-term impact on biotech investments originating from China? Yes No Unsure

23 While life science leaders do not expect the U.S./China trade war to have an impact on their regional strategies, they do expect it will have long-term impact on investments coming from that region Investor and Executive Responses 60% 50% 40% % 20% 33.33% 7.58% 18.18% Negative Impact No Impact More than half of biotech leaders think the trade war with China will have no impact on their strategy for partnerships, investments, or expansion in this region 10% 0% 15.15% 13.64% 12.12% Yes No Unsure Investors Executives One third of biotech execuaves think the trade war will have a long term impact on investments originaang from China

24 Question 10: What impact will the UK exit from the EU in March 2019 have on investment in the regions below? United Kingdom, North America, European Union, Other Global Markets Increase Decrease No change

25 When the UK exits from the EU in March, investors expect to see a decrease in investments in the UK while other markets will see an increase or remain unchanged United Kingdom North America European Union Other Global Markets 10% 15% 76% 61% 34% 5% 30% 30% 41% 75% 19% 6% Increase Decrease No Change

Employment Trends & Salary Survey

Employment Trends & Salary Survey Employment Trends & Salary Survey 2017-18 in partnership with www.sciproglobal.com Contents Introduction to SciPro...3 Executive Summary...4 Section 1 Demographics...5-10 Section 2 Hiring Trends...11-18

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

AdAlta Limited (ASX:1AD) Quarterly Cash Flow Statement

AdAlta Limited (ASX:1AD) Quarterly Cash Flow Statement 31 January 2017 Company Announcements/Australian Securities Exchange AdAlta Limited (ASX:1AD) Quarterly Cash Flow Statement Highlights Received FDA Orphan Drug Designation for AD-114 in IPF Positive Pre-clinical

More information

Addressing access to healthcare

Addressing access to healthcare Addressing access to healthcare Karl Mahler Head Investor Relations René Imhof Head Operational Pricing Swiss Sustainability Leaders SRI Conference Buonas, 17 November 2014 This presentation contains certain

More information

The Funding Landscape for Small Biopharma Ventures,

The Funding Landscape for Small Biopharma Ventures, HEALTHCARE The Funding Landscape for Small Biopharma Ventures, 2010-2015 Trends, strategies and priorities By Gaurav Misra Gaurav Misra Gaurav Misra specializes in pharmaceutical licensing, valuations

More information

Sunesis Pharmaceuticals Reports Second Quarter 2014 Financial Results and Recent Highlights. VALOR Trial Reaches Prespecified Events for Unblinding

Sunesis Pharmaceuticals Reports Second Quarter 2014 Financial Results and Recent Highlights. VALOR Trial Reaches Prespecified Events for Unblinding Sunesis Pharmaceuticals Reports Second Quarter 2014 Financial Results and Recent Highlights August 5, 2014 7:00 AM ET VALOR Trial Reaches Prespecified Events for Unblinding Sunesis to Host Conference Call

More information

GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris

GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris Press Release GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris Capital increase of approximately 40 million, which may be increased to a maximum of approximately

More information

UNC KENAN-FLAGLER: DISCUSSION MATERIALS MARCH 2014

UNC KENAN-FLAGLER: DISCUSSION MATERIALS MARCH 2014 UNC KENAN-FLAGLER: DISCUSSION MATERIALS MARCH 2014 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

More information

Franklin Biotechnology Discovery Fund A (acc) USD

Franklin Biotechnology Discovery Fund A (acc) USD Franklin Discovery Fund A (acc) USD Franklin Templeton Investment Funds Fund Manager Report Equity Product Details 1 Fund Assets $2,125,578,204.37 Fund Inception Date 03/04/2000 Number of Issuers 93 Bloomberg

More information

Cytori Reports First Quarter 2014 Business and Financial Results

Cytori Reports First Quarter 2014 Business and Financial Results CYTORI THERAPEUTICS CONTACT Megan McCormick +1.858.875.5279 mmccormick@cytori.com Cytori Reports First Quarter 2014 Business and Financial Results San Diego, CA, May 12, 2014 Cytori Therapeutics (NASDAQ:

More information

Ipsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates

Ipsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates PRESS RELEASE Ipsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates Paris (France), 26 April 2018 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical

More information

ICON plc and subsidiaries

ICON plc and subsidiaries ICON plc and subsidiaries Interim financial statements Six months ended 30 June 2012 Registered number 145835 ICON plc and subsidiaries Interim Management Report and Condensed Consolidated Financial Statements

More information

0 Preliminary Results December Preliminary Results December March 2011

0 Preliminary Results December Preliminary Results December March 2011 0 Preliminary Results December 2010 Preliminary Results December 2010 23 March 2011 Agenda Introduction 2010 Results International business Acquisition of Atomic PR Citigate Grayling Red Huntsworth Health

More information

HEARING STATEMENT. United States Senate Committee on Banking, Housing, and Urban Affairs

HEARING STATEMENT. United States Senate Committee on Banking, Housing, and Urban Affairs HEARING STATEMENT United States Senate Committee on Banking, Housing, and Urban Affairs Spurring Job Growth Through Capital Formation While Protecting Investors December 1, 2011 Executive Summary The Biotechnology

More information

How to value your start-up Dr. Patrik Frei January 2016 San Francisco

How to value your start-up Dr. Patrik Frei January 2016 San Francisco How to value your start-up Dr. Patrik Frei January 2016 San Francisco Overview Introduction to Valuation Valuation of start-up companies Valuation of a therapeutic Product Q & A 2 Venture Valuation Mission

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month

More information

News Release. Transaction Highlights

News Release. Transaction Highlights News Release Proposed Acquisition of Shire plc by Takeda Creates a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan Better positions Takeda to deliver highly-innovative

More information

Heidelberg Pharma announces financial figures for fiscal year 2017 and provides business update

Heidelberg Pharma announces financial figures for fiscal year 2017 and provides business update PRESS RELEASE Heidelberg Pharma announces financial figures for fiscal year 2017 and provides business update Financials in line with guidance on the back of positive revenue performance Corporate actions

More information

GLOBAL BREXIT BAROMETER 2018

GLOBAL BREXIT BAROMETER 2018 GLOBAL BREXIT BAROMETER 2018 Tuesday 20 March 2018 Gary Baker, CFA, Managing Director EMEA and Industry and Policy Research, CFA Institute Rhodri Preece, CFA, Head of Industry Research, CFA Institute Will

More information

ehealth Inventory Report of Major Medical Health Plans Available Off of Government Exchanges

ehealth Inventory Report of Major Medical Health Plans Available Off of Government Exchanges ehealth Inventory Report of Major Medical Health Available Off of Government Exchanges February 2014 Introduction Beginning January 1, 2014, all new major medical health insurance plans were required to

More information

Biotech Financing Update. Dec 2017-Feb 2018

Biotech Financing Update. Dec 2017-Feb 2018 Biotech Financing Update Dec 2017-Feb 2018 Biotech Financing Update Overall figures These figures capture biotech financing data from December 2017 and take a first look at how the sector is doing in 2018

More information

Jefferies Global Healthcare Conference

Jefferies Global Healthcare Conference Jefferies Global Healthcare Conference June 7, 2012 2012 PAREXEL International Safe Harbor This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act

More information

Venture Capital and Company Valuations in Biotech

Venture Capital and Company Valuations in Biotech Venture Capital and Company Valuations in Biotech Venture Valuation VV AG Badenerstr. 18 8004 Zurich Switzerland Phone +41 (43) 321 86 60 Fax + 41 (43) 321 86 61 info@venturevaluation.ch Agenda - Swiss

More information

Small-Cap Research. Oncolytics Biotech Inc. November 28, 2017 John D. Vandermosten, CFA (ONCYF - OTCQX) Cash & Validation: REOLYSIN is Going to Asia

Small-Cap Research. Oncolytics Biotech Inc. November 28, 2017 John D. Vandermosten, CFA (ONCYF - OTCQX) Cash & Validation: REOLYSIN is Going to Asia Small-Cap Research November 28, 2017 John D. Vandermosten, CFA 312-265-9588 / jvandermosten@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Oncolytics Biotech Inc. Cash & Validation:

More information

Financing sources for life science projects and companies Dr. Aitana Peire May 2017 International Exploitation Training FFH2.

Financing sources for life science projects and companies Dr. Aitana Peire May 2017 International Exploitation Training FFH2. Financing sources for life science projects and companies Dr. Aitana Peire May 2017 International Exploitation Training FFH2.0, Prague Venture Valuation Mission Independent assessment and valuation of

More information

Market Allocation Platform Guiding investment decisions to maximize ROI. Tourism Economics

Market Allocation Platform Guiding investment decisions to maximize ROI. Tourism Economics Market Allocation Platform Guiding investment decisions to maximize ROI Tourism Economics core services Travel data and forecasts for 190 countries, 50 states, and 300 cities Policy analysis and recommendations

More information

What you need to know to succeed in doing deals and fundraising Dr. Patrik Frei May 2014 Seoul BioKorea

What you need to know to succeed in doing deals and fundraising Dr. Patrik Frei May 2014 Seoul BioKorea What you need to know to succeed in doing deals and fundraising Dr. Patrik Frei May 2014 Seoul BioKorea Overview Introduction to Valuation Valuation of a companies Valuation of a therapeutic Product Q

More information

Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% 1 and upgrades its guidance for full year 2018

Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% 1 and upgrades its guidance for full year 2018 Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% 1 and upgrades its guidance for full year 2018 Sales growth of 26.7% 1 for Specialty Care and 2.0% 1,2 for Consumer Healthcare

More information

Stifel Presentation November 2018

Stifel Presentation November 2018 Stifel Presentation November 2018 Disclaimer This presentation may contain certain forward-looking statements. Such statements reflect current views on, among other things, our markets, activities, projections,

More information

GLOBAL TRANSACTIONS FORECAST

GLOBAL TRANSACTIONS FORECAST 2018 GLOBAL TRANSACTIONS FORECAST Healthcare A BAKER MCKENZIE SECTOR REPORT Deal activity to surge amid strong market conditions and US tax reform Uncertainty in the wake of Brexit, the US presidential

More information

Radford Review: 2013 Say-on-Pay Results and Trends for the US Life Sciences Sector. One Firm. Complete Solutions.

Radford Review: 2013 Say-on-Pay Results and Trends for the US Life Sciences Sector. One Firm. Complete Solutions. Radford Review: 2013 Say-on-Pay Results and Trends for the US Life Sciences Sector One Firm. Complete Solutions. 2013 Say-on-Pay Snapshot Overall Russell 3000 Index Results Among Russell 3000 companies

More information

INSTITUTIONAL RESEARCH Biotechnology COMPANY UPDATE Member FINRA/SIPC

INSTITUTIONAL RESEARCH Biotechnology COMPANY UPDATE Member FINRA/SIPC INSTITUTIONAL RESEARCH Biotechnology COMPANY UPDATE Member FINRA/SIPC Toll Free: 561-391-5555 www.dawsonjames.com 1 North Federal Highway - Suite 500 Boca Raton, FL 33432 OncoSec Medical (Nasdaq/ONCS)

More information

MOLOGEN AG: Interim Financial Statements as of March 31, 2010

MOLOGEN AG: Interim Financial Statements as of March 31, 2010 MOLOGEN AG: Interim Financial Statements as of March 31, 2010 Content Foreword... Page 3 Interim management report for the period from January 1 to March 31, 2010... Page 5 Statement of financial position

More information

TEXAS MULTIFAMILY FOLLOW THE MONEY. THE CAPITAL MARKETS PERSPECTIVE Jeanette I. Rice, Americas Head of Investment Research February 12, 2016

TEXAS MULTIFAMILY FOLLOW THE MONEY. THE CAPITAL MARKETS PERSPECTIVE Jeanette I. Rice, Americas Head of Investment Research February 12, 2016 TEXAS MULTIFAMILY FOLLOW THE MONEY THE CAPITAL MARKETS PERSPECTIVE Jeanette I. Rice, Americas Head of Investment Research February 12, 2016 MULTIFAMILY ON TOP OF THE MARKET 2 MONEY IS FOLLOWING MULTIFAMILY

More information

Arix Bioscience plc Half-Yearly Report and Consolidated Interim Financial Statements Six months ended 30 June 2017

Arix Bioscience plc Half-Yearly Report and Consolidated Interim Financial Statements Six months ended 30 June 2017 Arix Bioscience plc Half-Yearly Report and Consolidated Interim Financial Statements Six months ended 30 June 2017 CEO s Statement A vote of confidence in the life science sector In February 2017, Arix

More information

Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights

Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights New York, NY November 9, 2016 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company

More information

Today s discussion. Traveler..domestic and international spending, origin, purpose and activities. Lodging data. Regional research

Today s discussion. Traveler..domestic and international spending, origin, purpose and activities. Lodging data. Regional research November 29, 2012 Today s discussion. Traveler..domestic and international spending, origin, purpose and activities Lodging data Regional research Massachusett's Travel and Tourism Top Line Numbers Direct

More information

GDP projections for major economies

GDP projections for major economies GDP projections for major economies 214-215 214 215 Australia 2.6% 2.7% Emerging markets 4.9% 5.2% Euro area 1.2% 1.5% Japan 1.4% 1.% United Kingdom 2.9% 2.5% United States 2.8% 3.% Source: IMF WEO. BRIC

More information

To Our Shareholders 33 44

To Our Shareholders 33 44 33 44 33 44 035 Letter from Stefan Oschmann 040 The Executive Board 042 Our Shares Letter from Stefan Oschmann 35 It is a great pleasure for me to write to you for the first time as Chairman of the Executive

More information

NEOVACS SUCCESSFULLY RAISES 6.0 MILLION IN PRIVATE PLACEMENT WITH U.S. BIOTECHNOLOGY INSTITUTIONAL INVESTORS

NEOVACS SUCCESSFULLY RAISES 6.0 MILLION IN PRIVATE PLACEMENT WITH U.S. BIOTECHNOLOGY INSTITUTIONAL INVESTORS PRESS RELEASE PRESS RELEASE PRESS RELEASE NEOVACS SUCCESSFULLY RAISES 6.0 MILLION IN PRIVATE PLACEMENT WITH U.S. BIOTECHNOLOGY INSTITUTIONAL INVESTORS Paris and Boston, July 31, 2017 7:30 am CET- Neovacs

More information

Franklin Biotechnology Discovery Fund A (acc) USD

Franklin Biotechnology Discovery Fund A (acc) USD Franklin Discovery Fund A (acc) USD Franklin Templeton Investment Funds Fund Manager Report Equity Product Details 1 Fund Assets $2,026,977,439.38 Fund Inception Date 03/04/2000 Number of Issuers 96 Bloomberg

More information

ADVERUM BIOTECHNOLOGIES, INC. (Exact Name of Registrant as Specified in its Charter)

ADVERUM BIOTECHNOLOGIES, INC. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event

More information

We believe in in the power of a vision. Investor Presentation

We believe in in the power of a vision. Investor Presentation We believe in in the power of a vision. Q1-2008 Investor Presentation Forward-Looking Statements Certain matters discussed in this presentation may be forward-looking statements within the meaning of the

More information

ERYTECH TO RAISE 70.5 MILLION IN A PRIVATE PLACEMENT TO U.S. AND EUROPEAN INVESTORS

ERYTECH TO RAISE 70.5 MILLION IN A PRIVATE PLACEMENT TO U.S. AND EUROPEAN INVESTORS PRESS RELEASE THIS DOCUMENT MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN. THIS PRESS RELEASE IS NOT INTENDED AS AN OFFER AND IS

More information

Galapagos reports record revenues and increased profitability in 2010

Galapagos reports record revenues and increased profitability in 2010 Regulated information 4 March 2011 Galapagos reports record revenues and increased profitability in 2010 Revenues 136.6 M (+29%) Net profit 4.4 M ( 09: 3.0 M) Operating profit 1.0 M ( 09: 1.7 M) Year end

More information

FOR IMMEDIATE RELEASE Contact: Ann Marie Gorden/Robert Nihen

FOR IMMEDIATE RELEASE Contact: Ann Marie Gorden/Robert Nihen cutting through complexity News FOR IMMEDIATE RELEASE Contact: Ann Marie Gorden/Robert Nihen June 24, 2014 KPMG LLP 201-505-6288/201-307-8296 agorden@kpmg.com / rnihen@kpmg.com CINCINNATI, CLEVELAND, ATLANTA

More information

VALUING YOUR OPPORTUNITY How industry and investors evaluate your project or company

VALUING YOUR OPPORTUNITY How industry and investors evaluate your project or company VALUING YOUR OPPORTUNITY How industry and investors evaluate your project or company Dr. Patrik Frei September 2015 Brisbane Overview Introduction Valuation of start-up companies Valuation of a therapeutic

More information

Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update May 10, 2018 Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MAY 10, 2018 AT 8:00 AM EDT BOSTON,

More information

ZipRealty, Inc. Supplemental Data Reclassification of Consolidated Statement of Operations

ZipRealty, Inc. Supplemental Data Reclassification of Consolidated Statement of Operations Reclassification of Consolidated Statement of Operations Effective January 1, 2007, for income statement presentation purposes, we have reclassified sales support and marketing expenses from general and

More information

Assets under management (as previously reported)

Assets under management (as previously reported) Assets under management (as previously reported) For completeness we have included below a five-year analysis of assets under management as previously reported. Going forward, this will be replaced by

More information

Next Edge Bio-Tech Plus Fund

Next Edge Bio-Tech Plus Fund Next Edge Bio-Tech Plus Fund Monthly Commentary as of January 31, 2019 Investing in companies of the future: A unique, well defined process of investing in North American small and mid-capitalization biotechnology

More information

** The operating loss for H is after exceptional costs of 41k relating to the termination of the Biomoti acquisition

** The operating loss for H is after exceptional costs of 41k relating to the termination of the Biomoti acquisition The Magdalen Centre The Oxford Science Park Robert Robinson Avenue Oxford OX4 4GA UK Tel 01865 784980 Fax 08701 671931 ("Physiomics" or "the Company") Interim Results Statement for the six-month period

More information

STADA: Strong growth in 1-9/2007: Sales +25%, operating profit +41%

STADA: Strong growth in 1-9/2007: Sales +25%, operating profit +41% Corporate News STADA: Strong growth in 1-9/2007: Sales +25%, operating profit +41% STADA interim report after 9 months of 2007: Important items at a glance Strong operative growth continues as expected

More information

Kite Pharma Reports First Quarter 2015 Financial Results

Kite Pharma Reports First Quarter 2015 Financial Results May 15, 2015 Kite Pharma Reports First Quarter 2015 Financial Results SANTA MONICA, Calif., May 15, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company

More information

Orion Interim Report Q1 Q2/2012

Orion Interim Report Q1 Q2/2012 Orion Interim Report Q1 Q2/2012 31 July 2012 Timo Lappalainen President and CEO This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not

More information

CHINA i2i GROUP WECHAT SURVEY

CHINA i2i GROUP WECHAT SURVEY 2017 CHINA i2i GROUP WECHAT SURVEY 88% 3 Million $3.4 Billion 690,000 875,000 94% 88% Are Millennials Age 18 39 More than 3 Million Annual International Travelers $3.4 Billion In Annual Shopping Spend

More information

Adequate Procedures: An International Overview

Adequate Procedures: An International Overview Adequate Procedures: An International Overview Rossana Buzzi, Invensys Jonathan Armstrong, Cordery SCCE 14th Annual Compliance and Ethics Institute 5 October 2014 Legal Disclaimer The views stated herein

More information

2015 Dining Trends Survey Results

2015 Dining Trends Survey Results 1 # of participants: 10,727 Gender: Male - 45% / Female - 55% Age: 20s -19% / 30s -17% / 40s -19% / 50s -19% / 60+ - 26% How many times do you typically eat out in restaurants for breakfast, lunch and

More information

Workshop Presentation: Deal and Product Valuations Nov 2017 NYC, RESI Agenda 1.Overview of product valuation 2.rNPV product valuation 3.Deal structure / Negotiation 4.Case Study 2 Company Mission Independent

More information

Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY November 9, 2018 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company

More information

Agenda. Venture Capital and Valuations

Agenda. Venture Capital and Valuations Venture Capital and Valuations Venture Valuation VV AG Badenerstr. 18 8004 Zurich Switzerland Phone +41 (43) 321 86 60 Fax + 41 (43) 321 86 61 info@venturevaluation.ch Agenda - Venture Capital - Why Valuation?

More information

Returns Based on a $100,000 Investment

Returns Based on a $100,000 Investment A Leading Developer of Stem Cell Treatment Centers Fact Sheet 2016 Bioscience Americas, LLC Fund Data: Series 1: $15,000,000 Minimum Investment: $25,000 Type: Holdings: ) Investor Benefits: Private placement

More information

Sustaining Innovation and Access in Europe. Nathalie Moll, Secretary General Brussels, 13 May 2014

Sustaining Innovation and Access in Europe. Nathalie Moll, Secretary General Brussels, 13 May 2014 Sustaining Innovation and Access in Europe Nathalie Moll, Secretary General Brussels, 13 May 2014 Who we are European Association of Biotechnology Industries Three sectors Red: Healthcare biotechnology

More information

LAIDLAW & COMPANY Est. 1842

LAIDLAW & COMPANY Est. 1842 LAIDLAW & COMPANY London New York San Francisco Boston EQUITY RESEARCH Company Report Cara Therapeutics (CARA - $14.70) CARA to Benefit from Important Licensing Agreement CARA recently announced that they

More information

Interim results for the six months ended 30 June 2017

Interim results for the six months ended 30 June 2017 Interim results for the six months ended 30 June 2017 Midatech Pharma plc September 2017 Disclaimer THIS PRESENTATION MAY NOT BE COPIED OR REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY

More information

Ipsen FY 2017 Results. February 15, 2018

Ipsen FY 2017 Results. February 15, 2018 Ipsen FY 2017 Results February 15, 2018 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates

More information

AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results

AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results Reports Full-Year Diluted EPS of $3.63 on a GAAP Basis; Adjusted Diluted EPS of $4.82, Reflecting Growth of 12.4 Percent

More information

Real Estate Investment Beyond(?) the Global Credit Crisis

Real Estate Investment Beyond(?) the Global Credit Crisis Real Estate Investment Beyond(?) the Global Credit Crisis James Valente (james.valente@ipd.com) Director, North America November 29 th 2011 2011 ipd.com Overview Variation in regional trends Global investment

More information

2012 SUMMARY REPORT PG 1

2012 SUMMARY REPORT PG 1 2012 SUMMARY REPORT PG 1 100 MILLION PEOPLE City of Hope scientists helped create medicines that benefit 100 million people worldwide each year. 15 FIRST-IN-HUMAN CLINICAL TRIALS City of Hope has created

More information

Pharming Group reports financial results for the first nine months of 2017

Pharming Group reports financial results for the first nine months of 2017 Pharming Group reports financial results for the first nine months of 2017 Strong increase in revenues boosts operating profitability and positive cash flow Strong outlook with increasing revenues expected

More information

How A No-Deal Brexit Would Affect Life Sciences Cos.

How A No-Deal Brexit Would Affect Life Sciences Cos. Portfolio Media. Inc. 111 West 19 th Street, 5th Floor New York, NY 10011 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com How A No-Deal Brexit Would Affect Life Sciences

More information

1 sur 9 26/07/ :19

1 sur 9 26/07/ :19 1 sur 9 26/07/2012 13:19 Print Page Close Window Press Releases Celgene Reports Second Quarter 2012 Operating and Financial Results Total Revenue of $1.37 Billion and Net Product Sales of $1.34 Billion,

More information

PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)

PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

evestment Alliance, LLC - All Rights Reserved

evestment Alliance, LLC - All Rights Reserved HEDGE FUND REGIONAL COMPOSITIONS Summary The following pages rank the regional distribution of active hedge fund firms and their active products (funds), based on information contained in evestment s research

More information

ASTRAZENECA REFINES ITS FINANCIAL REPORTING IN LINE WITH EVOLVING BUSINESS MODEL

ASTRAZENECA REFINES ITS FINANCIAL REPORTING IN LINE WITH EVOLVING BUSINESS MODEL 6 March 2015 ASTRAZENECA REFINES ITS FINANCIAL REPORTING IN LINE WITH EVOLVING BUSINESS MODEL trazeneca today announces an update to the presentation of its Statement of Comprehensive Income, which will

More information

Page 1 of 6 Contact Us Legal Sitemap Search About Us Soliris & PNH R & D Investors Careers News Archives Highlights Media Kit Inquiries Alexion Reports Second Quarter 2011 Results -- Soliris (eculizumab)

More information

Syneos Health, Inc. Investment Research Presentation

Syneos Health, Inc. Investment Research Presentation Syneos Health, Inc. Investment Research Presentation NasdaqGS: SYNH Month Sector: Day, Healthcare 20XX Senior Analyst: Jose Grullon Junior Analysts: Garbis Chekerdjian, Ignacio Fimbres Spring 2018 1 Valuation

More information

1. The Board of Directors' report on the Company's activities in the past year.

1. The Board of Directors' report on the Company's activities in the past year. AGENDA 1. The Board of Directors' report on the Company's activities in the past year. 2. Presentation of the Annual Report for adoption. 3. A proposal from the Board of Directors regarding the application

More information

NeuroVive resolves on a Rights issue of MSEK for continued drug development, and new publication date of the 2018 Year End Report

NeuroVive resolves on a Rights issue of MSEK for continued drug development, and new publication date of the 2018 Year End Report NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report Lund, Sweden, 10 December 2018, NeuroVive Pharmaceutical AB (publ)

More information

The Economic Backdrop When will this cycle end?

The Economic Backdrop When will this cycle end? The Economic Backdrop When will this cycle end? How far are we into the current economic expansion? Current expansion in 8 th year; 4 th longest since 1960 Length of economic expansions (months) Apr-91-Feb-01

More information

Capital Link CEF and Global ETF Forum April 27, 2017

Capital Link CEF and Global ETF Forum April 27, 2017 Capital Link CEF and Global ETF Forum April 27, 2017 THW THQ HQH HQL Forward Looking Statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other

More information

Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2018

Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2018 Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2018 Exclusive research agreement signed with Magenta for the development of Antibody Targeted Amanitin Conjugates License

More information

AVEO Reports First Quarter 2018 Financial Results and Provides Business Update

AVEO Reports First Quarter 2018 Financial Results and Provides Business Update AVEO Reports First Quarter 2018 Financial Results and Provides Business Update CAMBRIDGE, Mass. May 8, 2018 AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March

More information

SECTION 03: Quantitative analysis

SECTION 03: Quantitative analysis Researc Researc Researc 8m 9% 7m 7,689,644.9 8% 7% 6m 588,574,879.6 6% 5% 4% 3% 2% Amount 5m 4m 3m 258,489,815.2 381,51,62.7 494,118,741. 212 213 1% % 2m 1m 7,77,161.45 139,871,673.7 26-7 27-8 28-9 29-1

More information

Competitive Alternatives. Special Report: Focus on Tax Edition. competitivealternatives.com. Corporate Sponsors

Competitive Alternatives. Special Report: Focus on Tax Edition. competitivealternatives.com. Corporate Sponsors Competitive Alternatives Special Report: Focus on Tax 2012 Edition competitivealternatives.com Corporate Sponsors ii Competitive Alternatives 2012 Contents 1. Summary 1 2. Measuring Total Tax Costs 6 3.

More information

2018 Edelman Trust Barometer

2018 Edelman Trust Barometer 2018 Edelman Trust Barometer Snapshot Australia #TrustBarometer Trust Index A World of Distrust Average trust in institutions, general population, 2017 vs. 2018 Global Trust Index remains at distruster

More information

The Global Tax Reset 2017 Audit Committee Symposium

The Global Tax Reset 2017 Audit Committee Symposium The Global Tax Reset Copyright 2017 Deloitte Development LLC. All rights reserved. 2017 Audit Committee Symposium Anticipate. Navigate. Focus. 1 The Global Tax Reset General context Multinational companies

More information

Building global leaders in healthcare...

Building global leaders in healthcare... Building global leaders in healthcare... Annual report and accounts 2017 ... to deliver transformational treatments for patients Syncona Syncona is a leading FTSE 250 company focused on investing in and

More information

UCB half year results 2012: On track for growth

UCB half year results 2012: On track for growth UCB half year results 2012: On track for growth In the first half 2012, total revenue increased by 2% 1 to EUR 1 706 million. Cimzia, Vimpat and Neupro reaching combined net sales of EUR 413 million (+45%

More information

Nilfisk Q2 Interim Report 2018 Webcast presentation August 14

Nilfisk Q2 Interim Report 2018 Webcast presentation August 14 Webcast presentation August 14 Agenda 1 2 3 4 5 Highlights Business unit update Financials Outlook 2018 Q&A 2 Strong financial performance in Q2 Financial highlights Strong financial performance with organic

More information

Small-Cap Research. Oncolytics Biotech Inc. April 12, 2017 John D. Vandermosten, CFA (ONCYF - OTCQX) REOLYSIN Clinical Development Plan SUMMARY DATA

Small-Cap Research. Oncolytics Biotech Inc. April 12, 2017 John D. Vandermosten, CFA (ONCYF - OTCQX) REOLYSIN Clinical Development Plan SUMMARY DATA Small-Cap Research April 12, 2017 John D. Vandermosten, CFA 312-265-9588 / jvandermosten@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Oncolytics Biotech Inc. REOLYSIN Clinical

More information

Africa Pharmaceutical

Africa Pharmaceutical Africa Pharmaceutical (title Sector: ) Opportunities and Challenges Dr Feng Zhao Manager, Health Division Human Development Department, African Development Bank 1 The New Africa Economy Africa Rising:

More information

Multifamily Outlook. United States Fall 2014

Multifamily Outlook. United States Fall 2014 Multifamily Outlook United States Fall 2014 Markets continue to perform at peak levels... with nearterm, pocketed softening on the horizon On the heels of seven quarters of peak-level investment sale volumes,

More information

Session 11. Fiscal Policy

Session 11. Fiscal Policy Session 11. Fiscal Policy Government size Budget balances Fiscal Policy over the business cycle Debt and sustainability Understanding Fiscal Policy: Government size Government size varies across countries.

More information

U.S. Investment Outlook

U.S. Investment Outlook U.S. Investment Outlook Quarterly Investor Research update Q2 2015 U.S. Investment overview 37% 21% 15% 15% U.S. cities dominating global investment activity Top 20 Cities for Transactional Volumes H1

More information

CYTRX CORPORATION (Exact Name of Registrant as Specified in its Charter)

CYTRX CORPORATION (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Earliest Event Reported)

More information

About this survey. less optimistic than other major economies. Marcoeconomic pressure in the Eurozone,

About this survey. less optimistic than other major economies. Marcoeconomic pressure in the Eurozone, Outlook April October 2013 About this survey is a regular survey of senior executives from large companies around the world, conducted by the Economist Intelligence Ernst & Young clients and contacts and

More information

LAIDLAW & COMPANY Est. 1842

LAIDLAW & COMPANY Est. 1842 LAIDLAW & COMPANY London New York San Francisco Stamford Ft. Lauderdale EQUITY RESEARCH Company Report Cytori Therapeutics (CYTX - $ 2.07) Management Updates on Lorem Vascular Partnership and Others This

More information

US Hotel Industry Overview. Chris Crenshaw

US Hotel Industry Overview. Chris Crenshaw US Hotel Industry Overview Chris Crenshaw ccrenshaw@str.com July 2014 (12 MMA): All Signs Point To A Sellers Market % Change Room Supply* 1.8 bn 0.8% Room Demand* 1.1 bn 3.4% Occupancy 63 % 2.6% A.D.R.*

More information

Clavis Pharma ASA. First Quarter Report 2008

Clavis Pharma ASA. First Quarter Report 2008 Clavis Pharma ASA First Quarter Report 2008 Clavis Pharma uses its proprietary Lipid Vector Technology (LVT) to develop new and superior pharmaceuticals by improving already established drugs. The Company

More information